Register by March 13th and SAVE $300*!
(Mention Promo Code: JZT974)
RegisterRequest BrochureView Website
Conference Chairman: Tony Dutta, Senior Vice President of Operations, IDISElite Speakers Include: Zareen Ahmed, Corporate Regulatory Affairs-Regulatory CMC, sanofi-aventis David Bernstein, Ph.D., Consultant, Bernstein CMC Regulatory Consulting Christina Butta, Senior Principal Scientist, Pfizer Inc Tiffany Cavallaro, Clinical Supply Planning Manager, Merck Scott Eaton, Regulatory CMC, Pfizer Inc Jim Krupa, Associate Director, Planning and Coordination, Cephalon Micheline Marshall, Director, Clinical Pharmacy, Wyeth Gail Owens, Corporate Regulatory Affairs-RCMC, sanofi-aventis Frank Reale, Associate Director, Worldwide Regulatory Coordination and Clinical Supplies, Merck John Simmons, CMC Consultant; Former Director, Office of New Drug Quality Assessment, FDA Mark Ware, Director, Clinical Trial Services, IDIS Jill Wechsler, Washington Editor, Pharmaceutical Executive Yolanda Bell, Global NAMP Business Process Owner, Amgen Chris Wilson, Chief Operating Officer, Keats Healthcare Ltd
www.cbinet.com/comparator
The First and Only Source for Invaluable Information on:
Market Dynamics Driving an Increase in Comparator Studies and Keys to Success
Selection:Register by 3/13/09 Standard
2-Day Conference $1695$1995
Conference Co-Sponsor:
http://www.idispharma.com/
2009 Sponsors:
http://www.myoderm.com/, http://www.myoderm.com/, http://www.almacgroup.com/pharmaservices/, http://www.adiramedica.com/, http://www.pharmarama.com/about.htm, http://www.bilcare.com/, http://www.keatshealthcare.co.uk/, http://www.multipharma.ch/
Offer not valid on workshop only or academic registrations.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.